Immutrin

📍 Cambridge, United Kingdom👥 6 employees💰 Last funded Oct 2022
Biotechnology Research
LinkedIn
Amyloidosis is a group of rare but very serious, usually fatal diseases caused by the aggregation of body’s own proteins to form amyloid deposits in vital organs. Immutrin Ltd is a Cambridge-based biotech company that is generating transformative antibody treatments for systemic and local amyloidosis.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Immutrin?
Immutrin has 1 investors on record on gritt.io.
When did Immutrin last raise funding?
The most recent investment in Immutrin recorded on gritt.io was in October 2022.
What industry is Immutrin in?
Immutrin operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Immutrin based?
Immutrin is headquartered in Cambridge, United Kingdom.